



**Joint Chinese University of Hong Kong-New Territories East Cluster
Clinical Research Ethics Committee**

香港中文大學-新界東醫院聯網 臨床研究倫理 聯席委員會

8/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, HK
Tel : (852) 2632 3935 / 2144 5926 Fax : (852) 2646 6653 Website : <http://www.crec.cuhk.edu.hk>

The Joint CUHK-NTEC CREC is an independent committee established by CUHK/NTEC and authorized to perform ethics and scientific review and oversight of clinical studies within the jurisdiction of CUHK/NTEC in accordance with its standard operating procedure and the principles of the Declaration of Helsinki and ICH Good Clinical Practice.

CREC Ref. No.: 2006.425-T

14 MAY '14

To: Prof. Wai Sang POON
Dept. of Surgery
Prince of Wales Hospital

This notice is issued by the Joint CUHK-NTEC CREC with respect to the application/submission by you, being the principal investigator of the following study at your study site:

- **Study Protocol Title:** Autologous Mesenchymal Stem Cell Therapy Trial in Stroke Patients
- **Investigator(s):**

Wai Sang POON	Hoi Tung WONG	Kent Kam Sze TSANG
Xian Lun ZHU	Gang LU	Anil Tejbhan AHUJA
George Kwok Chu WONG	Ho Keung NG	Ka Sing WONG

In accordance with our standard operating procedure, we have duly performed ethics and scientific review of your application/submission as detailed below:

- **Nature of Your Application/Submission:**

<input type="checkbox"/> Initial application	<input type="checkbox"/> Others:
<input type="checkbox"/> Amendments/changes	<input checked="" type="checkbox"/> Renewal
- **Mode of Review:**

<input type="checkbox"/> Full review	<input checked="" type="checkbox"/> Expedited review
--------------------------------------	--
- **Date of Initial/Renewal Approval:** 25 May 2014
- **Document(s) Reviewed:** See Schedule 1
- **Reviewer(s):** See Schedule 2

After due review by our reviewer(s), we hereby write to inform you of our decision on your application/submission as follows:

- **Decision:**

<input checked="" type="checkbox"/>	Application/Submission approved
<input type="checkbox"/>	Application/Submission approved with condition(s) (see condition(s) below)
<input type="checkbox"/>	Application/Submission approved with remark(s) (see remark(s) below)
<input type="checkbox"/>	Application/Submission approved with condition(s) and remark(s) (see condition(s) and remark(s) below)
- **Regular Progress Report(s) Required:** Every 12 months from the date of initial/renewal approval and during the period of the study if required



香港中文大學醫學院

Faculty Of Medicine

The Chinese University Of Hong Kong



醫院管理局
新界東醫院聯網

Hospital Authority
New Territories East Cluster



Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee

香港中文大學-新界東醫院聯網 臨床研究倫理 聯席委員會

8/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, HK

Tel : (852) 2632 3935 / 2144 5926

Fax : (852) 2646 6653

Website : <http://www.crec.cuhk.edu.hk>


You, being the principal investigator of the study at your study site, are reminded to comply with our requirements and to maintain communication with us during the period of the study by undertaking the principal investigator's responsibilities including (but not limited to):

- if the study is an industry-sponsored clinical study, submitting to us a copy of the fully executed indemnity agreement satisfying the Hospital Authority's requirement prior to commencement of the study (if it has not been submitted yet);
- observing and complying with all applicable requirements under our standard operating procedure ("IRB/REC SOP"), the Declaration of Helsinki and the ICH GCP (if applicable);
- submitting regular progress report(s) at the required intervals (as specified above) in accordance with the requirements in the IRB/REC SOP;
- not implementing any amendment/change to any approved study document/material without our written approval, except where necessary to eliminate any immediate hazard to the subjects or if an amendment/change is only of an administrative or logistical nature;
- notifying us of any new information that may adversely affect the rights, safety or well-being of the subjects or the proper conduct of the study;
- reporting any deviation from the study protocol or compliance incident that has occurred during the study and may adversely affect the rights, safety or well-being of any subject in accordance with the requirements in the IRB/REC SOP;
- submitting safety reports on all SAEs observed at your study site or SUSARs reported from outside your study site in accordance with the requirements in the IRB/REC SOP; and
- submitting a final report in accordance with the requirements in the IRB/REC SOP upon completion or termination of the study at your study site.

In addition to the above, you are also reminded to observe and comply with other applicable regulatory and management requirements including (but not limited to):

- if required by Hong Kong laws or regulations, obtaining a certificate for clinical trial through the Hong Kong Department of Health and complying with the associated requirements;
- obtaining the necessary consent from the management of your institution/department in accordance with the requirements of your institution/department;
- if required by local laws or regulations at conducting site out of IRB/REC's jurisdiction, obtaining an approval and complying with associated requirements;
- not representing to any third party or in any way likely to mislead any third party forming the view that the approval from the IRB/REC has any extraterritorial effect; and
- with due diligence ensuring your teams, staff, agents or whosoever connected with you to comply with the preceding requirements.

Yours sincerely,



 Envy Lee (Secretary)
 for and on behalf of
 The Joint CUHK-NTEC CREC

EL/ci

14 MAY '14

**Schedule 1
Documents Reviewed**

The documents reviewed by with respect to the said application/submission include:

(Not Applicable)

**Schedule 2
Reviewers List
Joint CUHK-NTFC Clinical Research Ethics Committee**

Male / Female (M/F)	Qualification	Occupation	Title and Name
M	BSc, MBBS, MD, MRCP(UK), FHKCP, FRCP, FRC(E), FRCP(G), FHKAM(Med), FCP, FACP	Professor, Department of Medicine and Therapeutics, CUHK	Prof. Brian TOMLINSON
M	MBBS (UNSW), FANZCA(Aust), FHKCA, FHKAM, Dip Pain Mgt(HKCA), MHSM(UNSW)	Consultant, Department of Anaesthesia and Intensive Care, PWH	Dr. Simon K.C. CHAN